Publications – Marika Nestor

Publications in DiVA

Publications in PubMed

Selected publications:

  1. Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One. 2014, 9(4):e94621.
  2. Haylock AK, Spiegelberg D, Nilvebrant J, Sandström K, Nestor M. In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study. EJNMMI Res. 2014, 4(1):11.
  3. Bondza S, Stenberg J, Nestor M, Andersson K, Björkelund H. Conjugation effects on antibody-drug conjugates: evaluation of interaction kinetics in real time on living cells. Mol Pharm. 2014, 11(11):4154-63.
  4. Stenberg J, Spiegelberg D, Karlsson H, Nestor M. Choice of labeling and cell line influences interactions between the Fab fragment AbD15179 and its target antigen CD44v6. Nucl Med Biol. 2014, 41(2):140-7.
  5. Spiegelberg D, Kuku G, Selvaraju R, Nestor, M. Characterization of CD44 variant expression in head and neck squamous cell carcinomas. Tumour Biol. 2014, 35(3):2053-62.
  6. Nilvebrant J, Kuku G, Björkelund H, Nestor M. Selection and in vitro characterization of human CD44v6-binding antibody fragments. Biotechnol Appl Biochem. 2012, Vol 59(5):367-380.
  7. Sandström K, Haylock AK, Spiegelberg D, Qvarnström F, Wester K, Nestor M. A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio. Int J Oncol. 2012, 40(5):1525-32.
  8. Björkelund H, Gedda L, Barta P, Malmqvist M, Andersson K. Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF. PLoS One. 2011, 6(9):e24739.
  9. Nestor M, Andersson K, Lundqvist H. Characterization of 111In and 177Lu-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay. J Mol Recognit. 2008, 21:179-183.
  10. Fortin MA, Nestor M, Salnikov AV, Heldin NE, Rubin K, Lundqvist H. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.  Eur J Nucl Med Mol Imaging. 2007, 34(9):1376-87.